Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)
Key facts
- Who runs it
- Annika Bergquist
- Where
- Sweden12 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 571 people enrolled
- Started
- 1 Oct 2020
- Expected to end
- 31 Mar 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Simvastatin 40mg
- Placebo oral tablet
- Record updated
- 5 September 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- PSC verified by cholangiography or liver biopsy, with or without irritable bowel disease (IBD)
- Men and women between ≥18 years and ≤75 years
- Written informed consent
- A magnetic resonance imaging (MRI) or Magnetic resonance cholangiopancreatography (MRCP) performed within 4 months prior to randomization
- Colonoscopy performed within 24 months prior to randomization, if known IBD
- For women of childbearing potential efficient contraceptive
Who cannot take part
- Subjects on waiting list for transplantation
- Previous variceal bleeding
- Previous hepatobiliary malignancy
- Intake of any type of statins within 3 months prior to randmization
- Transplanted subjects
- Subjects with secondary sclerosing cholangitis
- Known intolerance to simvastatin
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a randomized, double-blind, placebo controlled multicenter study.
Read full original descriptionShow less
A total of 700 patients will be included. After an updated powercalculation 560 was condidered enough
The study will include patients with primary sclerosing cholangitis (PSC) for daily intake of 40 mg simvastatin/placebo for 5 years. The aim is to study effect of prognosis of PSC by long term intake of simvastatin. Outcome measures are death, liver transplantation, cholangiocarcinoma or bleeding from esophageal varices.
Subjects will be randomized (1:1) between Simvastatin and placebo.
The 2 groups in the trial
- SimvastatinTreatment being tested
Simvastatin 40 mg administered orally daily for 5 years.
Treatment: Simvastatin 40mg
- PlaceboPlacebo, for comparison
Placebo for Simvastatin 40 mg administered orally daily for 5 years.
Treatment: Placebo oral tablet
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Simvastatin on the Prognosis of Primary Sclerosing Cholangitis (PSC); A Randomized, Double-blind, Placebo Controlled Multicenter Study
- Publications
- Dietary Habits of Individuals With Primary Sclerosing Cholangitis-Poor Fat-Soluble Vitamin Intake and Dietary Quality.Liver international : official journal of the International Association for the Study of the Liver, 2025
- Record updated
- 5 September 2025